Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Financials
Fierce Pharma
Sarepta, despite key trial flop, will seek full nod for DMD meds
Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.
Angus Liu
Nov 4, 2025 7:56am
Fierce Pharma
Sarepta extends $700M debt to 2030 amid Elevidys uncertainty
Aug 21, 2025 10:52am
Fierce Pharma
New Incyte CEO takes 'fresh look' at business, outlines BD plan
Aug 4, 2025 11:16am
Fierce Pharma
AbbVie will continue to pursue external innovation for long-term
Jul 31, 2025 11:44am
Fierce Pharma
BMS touts commercial execution, reckons with clinical setbacks
Jul 31, 2025 11:10am
Fierce Pharma
Novo Nordisk names new CEO as it cuts sales, profit outlook
Jul 29, 2025 10:10am
